BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global technology company, today announced the completion of its acquisition of Accuri Cytometers, Inc., an Ann Arbor, Michigan-based company that develops and manufactures personal flow cytometers for researchers.
The acquisition expands BD's presence into the emerging affordable personal flow cytometer space, and helps expand the use of flow cytometry technology by researchers in regions of the world where ease of use and affordability are critical.
"The acquisition of Accuri Cytometers complements and broadens BD's offerings for life scientists by making flow cytometry more accessible to a wider audience of scientists and clinicians," said William Rhodes, President, BD Biosciences. "This includes researchers in scientific disciplines that have not traditionally used flow cytometry, such as environmental sciences, microbiology and marine biology."
The financial impact of the acquisition on fiscal year 2011 earnings has been incorporated into the guidance BD provided during its earnings call on February 8, 2011.
BD (Becton, Dickinson and Company)